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point of metabolic control in this pathway.
The proposal of a new intestinal signaling
mechanism which may contribute to the
maintenance of an adequate bile acid
pool by Inagaki et al. (2005) provides a
new thrust to the field.
The major pathway of bile acid bio-
synthesis is controlled by the activity of
the microsomal enzyme cholesterol 7α
hydroxylase (CYP7A1; Chiang, 2004).
The transcriptional control of this gene
is complex and still not fully understood.
Bile acids activate the nuclear receptor
farnesoid X receptor (FXR) in the liver,
which indirectly results in the repression
of Cyp7a1 transcription by the orphan
nuclear receptor small heterodimer part-
ner (SHP) partnered to the liver receptor
homolog-1 (LRH-1). FXR/SHP-indepen-
dent regulators of CYP7A1 expression,
such as PPAR-α and pregnane X recep-
tor have also been documented. In addi-
tion, in rodents—but not in humans—the
transcription of Cyp7a1 is stimulated by
cholesterol metabolites via the liver X re-
ceptor (LXR). Recently, the fibroblast
growth factor FGF19, which is under the
control of FXR, through its interaction
with its receptor FGFR4, has been shown
to downregulate CYP7A1 (Holt et al.,
2003, Yu et al., 2000, 2005). Besides
Cyp7a1, many of the genes modulating
the dynamics of enterohepatic circula-
tion of bile acids are also FXR regulated,
indicating the importance of controlling
their activity in response to bile acid
concentrations (Figure 1). Until now,
some of the previous observations in the
field had been difficult to reconcile. For
instance, blocking the intestinal flow of
bile acids by ligation of the bile duct
increases CYP7A1 expression and ac-
tivity, despite resulting in high concen-
trations of bile acids in the liver (Gustafs-
son, 1978), while reinfusion of bile acids
into the intestine rapidly downregulates
CYP7A1 expression, an effect that is not
seen upon intravenous or even portal
administration of bile acids (Pandak et
al., 1991).
Inagaki et al. (2005) now show that the
mouse ortholog of FGF19, FGF15, is ex-
pressed in the small intestine, but not in
the liver, and that it is regulated by FXR
(Li et al., 2005). Infusion of FGF15 re-
sults in repression of Cyp7a1 and down-
regulation of CYP7A1 activity and fecal
bile acid excretion through a mechanism
involving FGFR4 and, at least partly,
SHP. The authors propose that the syn-
thesis and release of FGF15 in the small
intestine functions as an enterohepatic
signal which senses bile acid uptake
and regulates hepatic bile acid synthesis
in an “endocrine” loop. This hypothesis
may be helpful in explaining some of the
contradictory observations on the regu-
lation of bile acid synthesis mentioned
above.
Further studies will have to elucidate
the detailed mechanisms of how FGF15/
19 and FGFR4 exert their effect on
CYP7A1 expression and activity and
how this potential pathway may overlap
with bile acid/FXR regulation. It will also
be important to characterize the cells
expressing FGFs and the details of their
secretion. The development of an assay
to measure circulating FGFs will be cru-
cial in understanding how FGFs may act
as intestinal hormones and whether this
phenomenon is relevant in humans.
The possible presence of a gut-liver
signaling pathway may additionally help
in the understanding of how distinct and
rapid diurnal variation in bile acid syn-
thesis is controlled. Recent studies in
humans have established that bile acid
production displays two distinct peaks
during daytime, with variations unrelated
to feeding (Gälman et al., 2005). It is
probable that this pattern is induced by
a “clock function” from the hypothala-
mus and turned off by postprandial in-
flow of bile acids in the portal vein or,
alternatively, by an inflow of gut-derived
FGF. The potential role of intestinal sig-
naling to the liver by FGF (and other
molecules) has added a new promising
dimension to the ancient concept of en-
terohepatic circulation of bile.
Bo Angelin
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Transducer of regulated CREB activity (TORC) proteins promote transactivation by the cAMP response element binding
protein (CREB) and mediate effects of cAMP agonists on gene expression. Koo et al. now report that TORC phosphoryla-
tion and nuclear/cytoplasmic shuttling play a key role in the regulation of gluconeogenesis by cAMP. Control of TORC
phosphorylation and function may integrate the effects of multiple factors involved in metabolic control, including cAMP
agonists, insulin, and AMP kinases. TORCs, and kinases affecting TORC function, are promising new therapeutic targets
for the treatment of diabetes mellitus.210 CELL METABOLISM : OCTOBER 2005
P R E V I E W SThe ability to stimulate gluconeogenesis
is critical for the adaptation to fasting,
and, conversely, unrestrained hepatic
glucose production is an early step in
the development of diabetes mellitus.
Recent studies by Marc Montminy and
coworkers at the Salk Institute have pro-
vided new insight into the molecular
mechanisms contributing to the regula-
tion of gluconeogenesis by cAMP ago-
nists and, possibly, other key regulators
of energy metabolism and hepatic gene
expression, including insulin and AMP
kinase (Koo et al., 2005).
Glucagon acts through cAMP and
protein kinase A to enhance transactiva-
tion by the cAMP response element bind-
ing protein (CREB) and stimulate the
expression of gluconeogenic genes, in-
cluding phosphoenolpyruvate carboxy-
kinase (PEPCK) and glucose-6 phos-
phatase (G6Pase), while insulin opposes
this function. Previous studies have
identified several mechanisms by which
glucagon and insulin can modulate the
transcriptional activity of CREB (Figure
1). CREB dimerizes through a leucine
zipper domain that is also involved in
DNA binding. Phosphorylation of the
Ser133 residue of CREB promotes the
recruitment of the CREB binding protein
(CBP) coactivator protein or its closely
related paralog, p300, through interac-
tion with the Kix domain (Chrivia et al.,
1993). Phosphorylation of Ser436 near
the Kix domain of CBP may mediate
some of the effects of insulin on cAMP-
stimulated gene expression (Zhou et al.,
2004), and phosphorylation of Ser1871
of CBP (Ser1834 in p300) also modu-
lates the function of CBP/p300(Guo et
al., 2001; Huang and Chen, 2005).
Koo et al. now report that another
family of CREB-interacting proteins, the
transducers of regulated CREB activity
(TORCs), plays a critical role in the rapid
regulation of CREB in response to hor-
monal signals and in promoting gluco-
neogenesis(Koo et al., 2005). TORC pro-
teins were recently identified by several
laboratories screening for factors that
stimulate CREB activity (Conkright et al.,
2003; Iourgenko et al., 2003). TORCs in-
teract with the leucine zipper region
of CREB through a coiled-coil domain
and stabilize its interactions with the
TAFII130 coactivator protein, thereby en-
hancing CREB transcriptional activity
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mCELL METABOLISM : OCTOBER 2005Conkright et al., 2003). In β cells,
ORC2 was shown to mediate the syn-
rgistic effects of cAMP agonists (in-
luding glucagon-like peptide-1) and
lucose on gene expression (Screaton
t al., 2004). Like many factors involved
n gene regulation, TORCs are phospho-
roteins that shuttle in and out of the nu-
leus (Screaton et al., 2004). Phosphory-
ation of the Ser171 residue of TORC2
romotes the binding of 14-3-3 adaptor
roteins and disrupts the function of a
earby nuclear localization signal, thereby
esulting in its cytoplasmic retention and
uppressing gene transactivation (Screa-
on et al., 2004). Analysis of TORC-asso-
iated kinases revealed that salt-induc-
ble kinases (SIKs) phosphorylate Ser171
Screaton et al., 2004). Interestingly, PKA
an phosphorylate and suppress the
unction of SIKs (Figure 1). This provides
mechanism by which cAMP agonists
an suppress Ser171 phosphorylation
nd, thereby, promote TORC nuclear lo-
alization and upregulation of CREB tar-
ets. In the β cell, glucose-induced
alcium signaling also contributes to
uclear localization of TORCs, due to
alcineurin-mediated dephosphorylation
f other sites involved in 14-3-3 binding
Screaton et al., 2004).
Koo et al. now report that TORC2 also
lays an important role in promoting
asting hepatic gluconeogenesis, and
hat TORC phosphorylation and nuclear/
ytoplasmic shuttling may be a focal in-
egration point for multiple factors regu-
ating gene expression in the liver, in-
luding glucagon, insulin, and AMP
inase (Koo et al., 2005). Initial studies
evealed that both insulin and glucagon
romote the phosphorylation of the
er133 residue of CREB, resulting in the
ecruitment of CBP to the PEPCK and
6Pase promoters. This suggests that
REB phosphorylation and its associa-
ion with CBP do not explain how insulin
nd glucagon exert opposing effects on
luconeogenic gene expression. Studies
ith knockin mice where the Kix domain
f CBP is disrupted provided further
upport for the concept that the CREBP-
BP interaction is not essential for the
ctivation of gluconeogenic gene ex-
ression required for maintaining normal
asting glucose levels (Koo et al., 2005).
hese findings suggest that some other
odulator(s) of CREB activity must be
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nmportant in regulating gluconeogenesis
n fasting: enter TORC2, the predomi-
ant TORC protein expressed in the
iver.
Koo et al. find that glucagon rapidly
uppresses the phosphorylation of Ser171
nd promotes the nuclear targeting of
ORC2 in the liver. In contrast, insulin in-
reases Ser171 phosphorylation and
romotes the cytoplasmic localization
f TORC2, suggesting that differential
hosphorylation of TORC2 may be im-
ortant in mediating the opposing ef-
ects of glucagon and insulin on CREB-
ediated gene expression and gluconeo-
enesis. Studies with adenoviral vectors
emonstrate that overexpression of
ORC2 stimulates gluconeogenic gene
xpression both in vivo and in isolated
epatocytes, while knocking down TORC2
xpression with siRNAs can disrupt the
ffects of glucagon and cAMP agonists
n gene expression and suppress fast-
ng blood glucose levels. These results
rovide important physiological evi-
ence that TORC2 plays an important
ole in mediating the effects of cAMP on
luconeogenic gene expression and in
egulating fasting blood glucose levels.
Several other interesting observations
erit further discussion. First, TORC2 is
hown to stimulate the expression of the
GC-1α coactivator protein, which also
ontributes to the regulation of gluco-
eogenic genes (Yoon et al., 2001).
ORC2 stimulates the expression of
IK1, the salt-inducible kinase that phos-
horylates Ser171 in the liver. The in-
uction of SIK1 (downstream from PGC-
α) subsequently results in increased
hosphorylation of TORC2, providing a
eedback loop by which cAMP, TORC2,
nd PGC-1α may regulate each other
nd limit their effects on gene expres-
ion and metabolism.
SIK1 is a member of the family of AMP
inase-related kinases, and Ser171 re-
ides within a predicted AMPK phos-
horylation site. Koo et al. go on to
how that Ser171 is phosphorylated by
MPK and that Ser171 phosphorylation
ediates the effects of AMPK agonists
n nuclear/cytoplasmic shuttling of TORC2
nd gluconeogenic gene expression.
hese findings suggest that TORC phos-
horylation may mediate effects of a
umber of factors, including metformin,211
P R E V I E W SFigure 1. Regulation and function of transducers of regulated CREB activity (TORCs)
TORC proteins (yellow ovals) interact with the leucine zipper domain of CREB and help to recruit the coactiva-
tor TAFII130 and thereby stimulates transcription. TORC2 stimulates the expression of PGC-1α, which acts
downstream to help stimulate the expression of the PEPCK, G6Pase, and salt-inducible kinase 1 (SIK1).
Phosphorylation of Ser133 in CREB recruits the CREB binding protein (CBP) coactivator through interaction
with the Kix domain, and phosphorylation of several sites in CBP modulates transactivation by CREB. The
phosphorylation of TORCs by SIKs and AMPK promotes its cytoplasmic localization and suppresses gene
transactivation. cAMP enhances the phosphorylation of SIKs and suppresses their function; this can result in
decreased phosphorylation of TORCs and thereby promotes their translocation to the nucleus and association
with CREB. Insulin may limit the function of TORCs by promoting their phosphorylation and thereby antago-
nize the ability of cAMP to stimulate gene expression.
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AMPK activity and suppress gluconeo-
genesis in the liver.
These studies provide important in-
sights into the mechanisms regulating
gluconeogenesis through CREB. TORC
proteins are also likely to be important in
the regulation of other metabolic path-
ways by CREB, and in settings where
CREB may contribute to the regulation
of cellular proliferation, including β cells
(Screaton et al., 2004) and in certain neo-
plasias (Conkright and Montminy, 2005).
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b212ther factors, including FoxO proteins,
ave recently received attention in medi-
ting early events in the regulation of glu-
oneogenic gene expression (Barthel et
l., 2005). The identification of TORCs as
ediators of hormone-regulated gluco-
eogenesis, and of the specific kinases
hat regulate TORC phosphorylation and
unction, are important advances in this
rea of metabolism and may provide
ew targets for the treatment of dia-
etes.
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